Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Rapid Evolution in GLP-1s and Therapeutics at ADA 2026

The American Diabetes Association (ADA) will meet for its 2026 Scientific Sessions on June 5, 2026, in New Orleans, Louisiana. Clinicians from all over the country will meet to share updates on new treatments and drugs, debut pivotal technologies, and read out key trial data.

In advance of the onslaught of news, Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss more of the upcoming presentations already announced for the conference, including updates on GLP-1 therapies and the hosts’ own sessions.]

Check out the full episode on what to watch at ADA 2026 

In this segment, Isaacs and Bellini reflect on the rapidly evolving therapeutic landscape in diabetes, obesity, and cardiometabolic disease, emphasizing the expanding pipeline of incretin-based therapies and the excitement surrounding next-generation agents currently under investigation. They discuss emerging treatments including survodutide, maritide, tirzepatide, and combination therapies such as cagrilintide with semaglutide, noting the steady stream of new data demonstrating benefits that extend well beyond glycemic control alone. The conversation highlights growing anticipation around future triple-agonist therapies and other novel mechanisms that may further improve outcomes across multiple diabetes-related comorbidities.

A central theme of the discussion is the importance of therapeutic choice and individualized care. The speakers note that in clinical practice, patient tolerance varies substantially among GLP-1 receptor agonists and related therapies. While some individuals may discontinue one medication because of gastrointestinal side effects or other tolerability concerns, many can successfully transition to a different agent within the class. As additional therapies become available, clinicians will have greater flexibility to tailor treatment selection based on patient-specific factors, including metabolic profile, cardiovascular risk, kidney disease, obesity severity, and treatment preferences. The speakers emphasize that expanding therapeutic options will ultimately improve the ability to personalize care and sustain long-term treatment success.

The discussion also focuses on the increasingly recognized multisystem benefits of these therapies. Beyond improving glycemic control and promoting weight loss, the speakers underscore evidence demonstrating reductions in cardiovascular risk and protection against kidney disease progression. They further reference benefits related to sleep apnea, obesity-associated joint disease, and broader metabolic dysfunction, characterizing these medications as transformative therapies capable of addressing the interconnected complications of diabetes and obesity simultaneously. The hosts repeatedly stress the importance of viewing diabetes treatment through a holistic cardiometabolic lens rather than focusing solely on glucose metrics.

The episode then transitions to previews of upcoming educational sessions at the American Diabetes Association Scientific Sessions. One speaker highlights an upcoming Medscape program centered on inhaled insulin, which will feature simulated patient-provider interactions demonstrating how clinicians can effectively discuss therapeutic options and reintroduce alternatives for individuals experiencing fatigue or burnout from automated insulin delivery systems. The discussion references ADA Standards of Care recommendations supporting patient-centered treatment decisions, including offering multiple technology and insulin delivery options over time as patient needs and preferences evolve. The speakers emphasize that flexibility and shared decision-making are critical to maintaining engagement with diabetes management technologies.

Another featured session will focus on skin complications associated with diabetes devices and wearable technologies. The speakers discuss the growing prevalence of adhesive reactions, skin irritation, and other dermatologic challenges related to continuous glucose monitors and insulin delivery systems. They note that successful technology use ultimately depends on patients being able to comfortably and consistently wear devices, making proactive management of skin-related complications essential for long-term adherence. The conversation emphasizes practical strategies to address these barriers and reinforces the importance of helping patients troubleshoot problems rather than abandoning effective technologies altogether.

The episode concludes with enthusiasm for the breadth of emerging research and educational programming at ADA, with the hosts expressing excitement about continuing to share new findings, expert interviews, and real-world perspectives on the future of diabetes technology and therapeutics.

Editor’s Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Videos

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover more of the upcoming news releases announced for ADA 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Type 2 Diabetes

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Biologic therapy has fundamentally reshaped the management of severe 

 over the past 2 decades, moving from a single approved agent — omalizumab — to a portfolio of 7 biologics targeting distinct inflammatory pathways with growing long-term safety and efficacy data. The composite biomarker framework underlying this approach has itself matured: the ORACLE2 meta-analysis, a patient-level analysis of 22 randomized controlled trial control groups including more than 6,000 patients, confirmed that elevated blood eosinophils and fractional exhaled nitric oxide (FeNO) are synergistically predictive of asthma attack risk and independently identify treatable T2 inflammation — establishing a quantitative basis for combining these biomarkers in clinical decision-making.¹ 

More recently, the twice-yearly anti-IL-5 biologic depemokimab received FDA approval in December 2025 based on the SWIFT-1 and SWIFT-2 trials,² and the NIMBLE non-inferiority trial published in the 

American Journal of Respiratory and Critical Care Medicine

 in 2026 provided the first evidence that patients already responding to mepolizumab or benralizumab can switch to depemokimab without loss of exacerbation control.³ In chronic obstructive pulmonary disease (COPD), dupilumab and mepolizumab have expanded the field into eosinophilic inflammatory phenotyping, with the BOREAS, NOTUS, and MATINEE trials establishing the evidentiary basis for add-on biologic therapy in patients who continue to exacerbate despite triple inhaled therapy.⁴˒⁵˒⁶

 convened a virtual clinical forum moderated by Nicola Hanania, MD, MS, Director of the Airways Clinical Research Center at Baylor College of Medicine and Chief of Pulmonary Critical Care at Ben Taub Hospital in Houston — a clinician investigator with firsthand experience in the pivotal biologic trials that have shaped both the asthma and COPD fields. Notably, Hanania served as a site investigator on the BOREAS and NOTUS dupilumab COPD trials and is a named contributor to the ORACLE2 consortium. The panel comprised 11 pulmonary and critical care physicians drawn from academic centers and community practices across Texas and Oklahoma, including fellows in training, program directors, and at least one community hospital pulmonologist practicing in a predominantly rural setting — a composition that grounded the discussion in the breadth of real-world implementation challenges.

The forum convened at a moment when the biologic treatment paradigm in both asthma and COPD is expanding faster than clinical infrastructure and payer systems have adapted. Depemokimab's approval has introduced a twice-yearly IL-5 option that addresses adherence barriers but has generated new clinical questions about the manageability of 6-month dosing intervals.² Mucus plug scoring — validated by CT-based data from the VESTIGE and CASCADE trials — is emerging as a candidate third biomarker for predicting biologic response in asthma, one that the moderator has already implemented in multicenter research protocols.⁷˒⁸ And GOLD 2026's formal endorsement of biologic escalation in eosinophilic COPD has elevated practitioner interest at a moment when most clinicians are still gaining comfort with the patient selection criteria.⁹ The group's discussion — spanning biomarker implementation, OCS stewardship, shared decision-making, biologic selection, and the frontier of COPD biologics — captured both the scientific momentum and the persistent practical friction that define this field in mid-2026.

First discussing asthma management, panelists have broadly adopted biomarker-driven prescribing but continues to navigate meaningful implementation gaps. Panelists across practice settings described FeNO as clinically valuable but inconsistently available — with academic sites integrating it into PFT workflows and county or community practices lacking equipment or trained staff. The composite biomarker approach endorsed by ORACLE and ORACLE2 — combining eosinophils and FeNO for synergistic risk stratification — resonated with Hanania, who described measuring all 3 T2 biomarkers (eosinophil count, FeNO, and IgE) as standard intake practice for new asthma patients at UT Health Houston. Biologic selection was described as a multifactorial process in which clinical phenotype and biomarkers provide the initial framework, but insurance formulary placement frequently determines the final agent. The group was broadly positive about dupilumab across age groups, with pediatric panelists noting strong adherence in teenagers due to co-improvement of atopic dermatitis and rhinitis, and adult clinicians describing durable OCS elimination and rare patients achieving clinical remission. Hanania identified the absence of formal step-down or inhaler discontinuation protocols as a significant unmet need — patients are achieving remission with no guideline to guide what comes next. Depemokimab drew split opinion: panelists from rural settings valued the logistical relief of twice-yearly dosing, while others expressed concern about managing clinical deterioration or adverse events over a 6-month interval without recourse to dose timing. Mucus plug data from VESTIGE and CASCADE — novel to roughly half the panel — was acknowledged as mechanistically explanatory but not currently practice-changing.

The COPD discussion was anchored by Hanania's direct trial experience. His observation that ~40% of BOREAS/NOTUS participants dropped below the ≥300 eos threshold between screening and randomization — yet showed comparable efficacy — raises the real-world question of how strictly to apply the label's cutoff in clinical practice, a point he framed as hypothesis-generating rather than practice-changing without confirmatory data. Panelists described routine eosinophil monitoring in COPD patients but acknowledged that pre-steroid measurement is difficult in practice, as most exacerbating patients have already received systemic steroids before their CBC is drawn. Real-world experience with mepolizumab in COPD was described as promising, with Brimah noting that the lower eosinophil eligibility threshold (≥150 cells/µL within the prior year) makes it easier to obtain insurance approval than dupilumab. Polling results from the COPD segment were notably consistent with prior forums in this series: clearer patient selection algorithms and payer support remained the most urgently needed improvements. Unmet needs raised in the closing discussion included the absence of approved targeted therapies for non-T2 COPD — a gap Hanania is actively investigating through trials at Baylor — and the untested but clinically observed possibility that early biologic intervention in eosinophilic COPD could attenuate long-term FEV1 decline, an outcome that only multi-year prospective data can confirm.

“Just like when these biologics started rolling out for asthma, they were really reserved for those very severe, uncontrolled asthmatics... And it seems like this is where we're starting with COPD, especially, with the GOLD guidelines aligning with that. And with asthma, we started seeing kind of a, let's start evaluating these patients earlier, getting them on biologics earlier [approach]. I feel like at 1 point, we will start noticing that these COPD patients, especially those type 2 inflammatory COPD patients, will benefit with a sooner approach,” a panelist said. “I feel like that's where we will be headed. It's really just trying to catch these patients earlier, before we have the exacerbations and hospitalizations to align with the guidelines.”

Meulmeester FL, Mailhot-Larouche S, Celis-Preciado C, et al; ORACLE2 Consortium. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. 

 2025;13(6):505-516. doi:10.1016/S2213-2600(25)00037-2

Jackson DJ, Wechsler ME, Menzies-Gow A, et al; SWIFT-1 and SWIFT-2 Investigators. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. 

 2024;391(24):2337-2349. doi:10.1056/NEJMoa2406673

Chupp G, Nagase H, Skowasch D, et al; NIMBLE Study Investigators. Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE). 

 Published online 2026. doi:10.1093/ajrccm/aamag031

Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. 

 2023;389(3):205-214. doi:10.1056/NEJMoa2303951

Bhatt SP, Rabe KF, Hanania NA, et al; NOTUS Investigators. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. 

 2024;390(24):2274-2283. doi:10.1056/NEJMoa2401304

Criner GJ, Celli BR, Bhatt SP, et al. Mepolizumab for COPD with exacerbations and eosinophilia. 

 2023;389(23):2127-2138. doi:10.1056/NEJMoa2303120

Porsbjerg CM, Dunican EM, Lugogo NL, et al. Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial. 

 Published online October 27, 2025. doi:10.1164/rccm.202410-1894OC

Diver S, McDowell PJ, Siddiqui S, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. 

 2024;3(3):EVIDoa2300135. doi:10.1056/EVIDoa2300135

Global Initiative for Chronic Obstructive Lung Disease. 

Global Strategy for Prevention, Diagnosis and Management of COPD: 2026 Report.

Articles

Experts unpack new asthma/COPD biologics, eosinophil+FeNO targeting, twice-yearly depemokimab switching, and payer hurdles in 2026 care.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Not Everything That Wheezes Is Asthma: Comorbidities, Mimickers, and the Right Time to Escalate

Plaque Imaging and the TRANSFORM Trial in Myocardial Infarction

Acute coronary syndrome (ACS), and more specifically 

, is among the most life-threatening diseases in the US, affecting roughly 1,045,000 patients annually. In addition to mortality, the condition contributes to a significant economic and health care burden.

However, a significant proportion of patients with MI do not exhibit common identifiable risk factors, and many are not provided with the necessary therapies to forestall negative outcomes. Many patients are only treated after coming to the clinic with apparent symptoms, which naturally leaves many patients without treatment.

At the American Society of Preventive Cardiology (ASPC) 2026 Virtual Imaging Symposium, Deepak Bhatt, MD, MPH, MBA, director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, spoke on plaque progression and regression as an imaging endpoint for MI.

“There’s been a tremendous amount of progress that’s been made in cardiology – we have terrific biological insight into what causes myocardial infarction, heart attacks,” Bhatt told 

. “But about 1 in 5 patients don’t have any identified risk factors. Some of them maybe have risk factors, but they weren’t identified as such. About 1 in 5 didn’t have any prior physician visits, and a majority – about 2/3 – weren’t on any preventive therapies, though they should have been. That’s the state of primary prevention right now in the US – it’s not really effective.”

In his presentation, Bhatt addressed the limitations of current risk analysis for asymptomatic patients, highlighting a variety of potential methods of screening to catch ACS before it progresses. In addition to plaque analysis, Bhatt also highlights cholesterol, triglycerides, lipoprotein(a), and residual diabetes as red flags for ACS progression, proposing potential interventions for each.

The leading pathological cause of ACS and, by extension, MI, is plaque rupture – several previous studies since 1980 have confirmed that plaque rupture is found in many of the most fatal MI cases. More recent decades have seen progress in utilizing imaging to identify precursor lesions that could progress to ACS, and investigators have hypothesized that local therapeutic interventions could prevent plaque rupture-induced thrombosis.

Experts are currently investigating plaque screening methods in patients with MI through the TRANSFORM trial, which is a prospective, randomized, open-blinded endpoint (PROBE), event-driven, pragmatic trial in patients at increased risk of 

 without known symptomatic cardiovascular disease. The trial will implement the Cleerly Coronary Artery Disease (CAD) Staging System to identify asymptomatic patients and personalize treatment to avoid cardiovascular events.

Bhatt expressed interest in the TRANSFORM trial, emphasizing the value of finding an effective method of screening for MI that will prevent the loss of traditionally asymptomatic patients. However, while Bhatt does support further screening tests in MI, he also addresses the inherent risks of implementing the technology early. Further testing is required to validate these devices and to determine their overall effectiveness.

“A lot of times, there can be a promising technology, and if you introduce it too soon, before there is the technical sophistication, the interpretive expertise, it doesn’t work,” Bhatt said. “The other risk is the Pandora’s box idea; that is, you don’t want to adapt a technology too soon, even though it’s intuitively appealing.”

Editors’ Note: Bhatt reports disclosures with GSK, Merck, Cereno Scientific, Angiowave, Boehringer Ingelheim, Novo Nordisk, and others.

Młynarska E, Czarnik W, Fularski P, Hajdys J, Majchrowicz G, Stabrawa M, Rysz J, Franczyk B. From Atherosclerotic Plaque to Myocardial Infarction-The Leading Cause of Coronary Artery Occlusion. Int J Mol Sci. 2024 Jul 2;25(13):7295. 

Bhatt D. Plaque Progression/Regression as a Treatment Target: Imaging Endpoints that Matter. Presented at the American Society of Preventive Cardiology 2026 Virtual Imaging Symposium, May 1, 2026. 

https://www.youtube.com/watch?v=t341F439OXI

Cleerly, Inc. A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events (TRANSFORM). ClinicalTrials.gov Identifier: NCT06112418. Updated May 20, 2026. Accessed May 20, 2026. 

https://clinicaltrials.gov/study/NCT06112418

Deepak Bhatt, MD, MPH, MBA, discusses his recent presentation at the ASPC 2026 Virtual Imaging Symposium and how plaque imaging can change the MI landscape.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Atherosclerotic Cardiovascular Disease

Vallerie McLaughlin, MD, is a professor of medicine and director of the Pulmonary Hypertension Program in the Division of Cardiovascular Medicine at the University of Michigan.

Ralinepag Achieves 55% Risk Reduction in PAH, With Vallerie McLaughlin, MD

Data from the phase 3 ADVANCE OUTCOMES trial presented at the 

American Thoracic Society (ATS) 2026 International Conference

 in Orlando, Florida, suggest ralinepag, an investigational once-daily oral prostacyclin receptor agonist, significantly reduced the risk of clinical worsening in patients with 

, including a largely pretreated population already receiving background combination therapy.

The event-driven, randomized, double-blind study enrolled 687 patients with PAH and evaluated ralinepag versus placebo on top of standard of care. Ralinepag achieved a 55% reduction in risk of adjudicated clinical worsening events compared with placebo (hazard ratio [HR], 0.45; 95% CI, 0.33 to 0.62; P <.0001).

“Ralinepag is highly potent. It's probably more potent than the currently available agents, and it's a once-daily agent, as opposed to twice daily,” Vallerie V. McLaughlin, MD, professor of cardiovascular medicine and director of the pulmonary hypertension program at the University of Michigan, said in an interview at ATS 2026. “We’re hoping that it would get higher levels of prostacyclin agonism in a patient and be potentially more effective.”

McLaughlin noted that prostacyclin pathway therapies remain foundational in PAH management, but clinical use has long been limited by tolerability and the need for careful dose adjustment. She described ralinepag as a potentially more patient-friendly approach that may allow for more effective prostacyclin pathway activation while maintaining individualized dosing strategies similar to existing clinical practice.

In addition to the primary endpoint, ralinepag demonstrated statistically significant improvements in key secondary outcomes. Investigators reported reductions in NT-proBNP levels from baseline to week 28 (24.3% reduction over placebo; 

 =.0013) and improvements in 6-minute walk distance (6MWD) (+20.4 m placebo-corrected difference; 

 =.0033). Additionally, ralinepag increased the odds of achieving clinical improvement by 47% (

The trial population included a high proportion of patients on background therapy, with many already receiving dual oral agents (80%). Despite this, ralinepag demonstrated benefit across multiple measures of disease progression, including time to hospitalization and other components of clinical worsening, suggesting additive efficacy in contemporary combination regimens.

McLaughlin emphasized that these findings may have implications for treatment sequencing in PAH, particularly as clinicians increasingly escalate therapy earlier in the disease course. She suggested that once approved, a once-daily oral prostacyclin receptor agonist could be integrated as an additional option for patients already receiving endothelin receptor antagonists and phosphodiesterase type 5 inhibitors, potentially as a third- or later-line therapy depending on risk profile and disease trajectory.

The ADVANCE OUTCOMES study also included individualized dose titration without a ceiling, reflecting real-world prostacyclin management principles. McLaughlin indicated that this approach helps balance disease symptoms with medication adverse events.

From a safety standpoint, findings were consistent with the known prostacyclin class profile, with no new safety signals identified. Adverse events were generally consistent with vasodilatory effects, and discontinuation rates were in line with expectations for this therapeutic class.

United Therapeutics plans on submitting a new drug application for ralinepag to treat PAH to the US Food & Drug Administration by the second half of 2026.

McLaughlin V, Ataya A, Albert J, et al. (

) ADVANCE Outcomes: A Phase 3, Randomized Clinical Trial Evaluating Ralinepag for Pulmonary Arterial Hypertension. Poster presented at ATS 2026 in Orlando, Florida, on May 20.

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026. Unither.com. Published 2026. Accessed May 20, 2026. 

https://ir.unither.com/press-releases/2026/05-17-2026-191518923

At ATS 2026, Vallerie McLaughlin, MD discusses ADVANCE OUTCOMES showing ralinepag reduced PAH clinical worsening risk by 55% in pretreated patients.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Patrick J. Strollo, MD, from the University of Pittsburgh Medical Center

What the Phase 3 AD109 Data Mean for Sleep Apnea, With Patrick John Strollo, MD 

Patrick John Strollo, MD, study author and sleep medicine physician at the University of Pittsburgh Medical Center, spoke with 

 at the American Thoracic Society (ATS) conference about key insights into the 

, including patient-reported outcomes, tolerability, and where AD109 might fit in the OSA treatment landscape if approved.

On the question of fatigue outcomes, Strollo noted that the primary analysis included the full trial population, as many of whom had mild OSA and relatively few fatigue complaints at baseline. When the analysis was narrowed to more symptomatic patients, specifically those with an Epworth Sleepiness Scale score above 10, the improvement in PROMIS fatigue scores was more pronounced. He also noted that fatigue can be difficult to measure in a society with widespread chronic sleep deprivation; AD109 may reduce sleep-disordered breathing, but it cannot reverse years of accumulated sleep debt.

Regarding the approximately 21–25% discontinuation rate due to adverse events, Strollo explained that the 3 main culprits, such as insomnia, dry mouth, and GI side effects, are consistent with the known profiles of both aroxybutynin and atomoxetine. He noted that the trial did not screen carefully for comorbid insomnia at enrollment, and patients with underlying insomnia may have been particularly susceptible to those effects. Patients who remained on treatment, however, tended to stay on drug and derive meaningful benefit.

Strollo highlighted the trial's notably broad population as a strength, 74% of participants had mild-to-moderate OSA, roughly a third were non-obese, and no specific signal emerged favoring the drug in any particular age, weight, demographic, or severity subgroup. He characterized AD109 as a first-in-class agent that, if approved, would represent another tool in the toolbox, particularly for the large population of patients who cannot tolerate or refuse PAP therapy and currently have limited options.

Disclosures: Strollo served as a consultant for Apnimed, Inspire Medical Systems, Cryosa, Somnomed, Philips Respironics, WisperSom, Biologix, Emmi Solutions, Zoll Medical Corporation, Restora, XII Medical and has received grant support through his institution from ResMed, Inspire Medical Systems, and Zoll Medical. He is also a non-Executive Director of Belluscura.

Patel S, Farkas R, Pho H, et al. (Poster Board # P194) Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea: A Pooled Analysis of the SynAIRgy and LunAIRo Phase 3 Trials. Poster presented at ATS 2026 on May 17.

Strollo P. AD109 Effective as Oral Agent for Obstructive Sleep Apnea, With Patrick John Strollo, MD. HCPLive. May 19, 2026. Accessed May 20, 2026. 

https://www.hcplive.com/view/ad109-effective-oral-agent-obstructive-sleep-apnea-patrick-john-strollo-md

This interview at ATS highlights key takeaways regarding new phase 3 data on AD109 for obstructive sleep apnea (OSA).

Obstructive Sleep Apnea

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Results from the phase 3 TETON-1 study presented at ATS 2026 showed inhaled treprostinil preserved lung function and reduced clinical worsening risk in IPF.

Pulmonary Fibrosis

TETON-1: Treprostinil Preserved Lung Function in Idiopathic Pulmonary Fibrosis

Gerard Criner, MD, is chair and professor of thoracic medicine and surgery at Lewis Katz School of Medicine at Temple University and director of the Temple Lung Center.

At ATS 2026, pooled phase 3 data showed mepolizumab reduced COPD exacerbations and hospitalizations in patients with blood eosinophil counts starting at 150 cells/µL.

Mepolizumab Reduced COPD Exacerbations, With Gerard Criner, MD

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the presentations that they’re looking forward to at ADA 2026.

Type 1 Diabetes

Incretins, Glucose Monitors, and Insulin Titration at ADA 2026

This interview at ATS 2026 highlights notable findings on the once-nightly oral pill, AD109, in obstructive sleep apnea (OSA).

AD109 Effective as Oral Agent for Obstructive Sleep Apnea, With Patrick John Strollo, MD

Charles L. Daley, MD, from National Jewish Health. 

At ATS 2026, phase 3b ENCORE findings showed amikacin liposome inhalation suspension achieved high culture conversion rates in newly diagnosed MAC lung disease.


ALIS Improves Symptoms in Newly Diagnosed MAC Lung Disease, With Charles Daley, MD

Kyle Staller, MD, MPH, is a gastroenterologist and the director of the Gastrointestinal Motility Laboratory at Mass General.

Kyle Staller, MD, MPH, explains new real-world data showing 41% of IBS-C patients change treatments at least once, with each switch driving higher HCRU and provider portal burden.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Treatment Cycling in IBS-C Drives Greater Healthcare Resource Utilization

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This potential new treatment option shows potential for patients living with obstructive sleep apnea.

Once-Nightly AD109 Pill Effective for Patients with Obstructive Sleep Apnea (OSA)

Carel le Roux, PhD, MSC, is a director of the Metabolic Medicine Group at the University College of Dublin School of Medicine.

Carel le Roux, PhD, MSC, discusses the investigative dual GLP-1/glucagon agonist’s weight loss efficacy in patients with obesity and overweight without T2D.

SYNCHRONIZE-1: Survodutide Achieves Significant Weight Loss Versus Placebo

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

FDA granted priority review to asundexian for secondary prevention after non-cardioembolic ischemic stroke or TIA.

FDA News

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

FDA Grants Priority Review to Asundexian for Secondary Prevention After Ischemic Stroke

Freed discusses the evidence supporting treatment of iron deficiency before anemia develops, the symptom burden of non-anemic iron deficiency including fatigue, restless legs syndrome, and pica.

Latest News

Rapid Evolution in GLP-1s and Therapeutics at ADA 2026

Not Everything That Wheezes Is Asthma: Comorbidities, Mimickers, and the Right Time to Escalate

Plaque Imaging and the TRANSFORM Trial in Myocardial Infarction

Ralinepag Achieves 55% Risk Reduction in PAH, With Vallerie McLaughlin, MD

What the Phase 3 AD109 Data Mean for Sleep Apnea, With Patrick John Strollo, MD